Home / Research library / TB-500
Compound guide
TB-500: what the research covers
The synthetic actin-binding region of thymosin beta-4, studied for cell migration and actin dynamics. What TB-500 is, how it differs from the full protein, and how it is supplied.
What TB-500 is — and is not
TB-500 is a synthetic seven-residue peptide, sequence LKKTETQ, corresponding to the actin-binding domain of thymosin beta-4. It is frequently described as being thymosin beta-4, and it is not. Thymosin beta-4 is a 43-residue protein with several activities; TB-500 reproduces one functional region of it.
That distinction has consequences for how the literature should be read. A great deal of the published research attributed to TB-500 was in fact carried out on full-length thymosin beta-4, and the two are not established as equivalent. Where a study reports an effect, it is worth checking which of the two was actually used, because the fragment lacks the remainder of the parent sequence and any activity that depends on it.
What the literature examines
The core mechanism is actin sequestration. Thymosin beta-4 is the principal G-actin sequestering protein in mammalian cells, holding a pool of monomeric actin available for rapid polymerisation. The LKKTETQ region is the part responsible for that binding, and the research interest follows from it: cell migration, cytoskeletal reorganisation and the movement of cells into a wound bed.
Downstream of that sit studies on angiogenesis, on inflammatory signalling, and on cardiac and corneal models. The mechanism is genuinely distinct from that of BPC-157, which is why the two are so often run together rather than as alternatives — one is studied for vascular signalling, the other for cell motility. Published work on the parent protein and the fragment is indexed on PubMed.
As with BPC-157, the evidence base is largely preclinical. Thymosin beta-4 itself has reached clinical trials in specific indications; TB-500 as a discrete entity has not, and the two should not be conflated when assessing the strength of the evidence.
How Amino Club supplies it
TB-500 is supplied lyophilised in sealed vials as TB-500, and combined with BPC-157 in the BPC-157 / TB-500 preparation and its metered intranasal form.
Each batch is specified at 99% purity or better by HPLC with mass spectrometric identity confirmation, released against the Certificate of Analysis carrying the batch number on the vial label. The lab testing page sets out the release sequence. For a seven-residue sequence, identity confirmation matters as much as the purity figure: short peptides are straightforward to synthesise and correspondingly easy to misidentify.
Sealed vials tolerate ambient transit and are held at -20°C long term. Reconstitution notes are on the product page and solvents under reconstitution supplies.
Related reading
The BPC-157 versus TB-500 comparison covers the mechanistic difference in detail. Both belong to the tissue and repair group, alongside ARA-290, KPV, LL-37 and VIP.
Every guide on this site is indexed in the research library. Certificates, storage and shipping are covered on the FAQ; institutional quantities through bulk and wholesale.
Research use only
TB-500 supplied by Amino Club is a laboratory reference material. It is not a medicine, not a supplement, and not for human or veterinary use, and no dosing guidance or administration protocol is provided. The full terms are in the research use policy.